BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call Summary
BioMarin's first-quarter revenue was impacted by order timing dynamics rather than demand shifts, with growth driven by the Amicus acquisition and product performance like Voxzogo and Galafold. Full-year guidance for 2026 has been raised to $3.825B–$3.925B.
Topics: acquisition impact operational performance pharmaceuticals revenue guidance